Neoadjuvant therapy for rectal cancer affects lymph node yield and status without clear implications on outcome: The case for eliminating a metric and using preoperative staging to guide therapy
Central Nervous System Neoplasms
Drug Delivery Systems
Molecular Targeted Therapy
This analysis reiterates that nodal yield in rectal cancer is multifactorial, with neoadjuvant therapy being a significant factor. Node yield and status were not significant predictors of overall survival. A nodal metric may not be clinically relevant in the era of neoadjuvant therapy, and guidelines for perioperative therapy may need reconsideration.